Rachel Strykowski, MD

Publications

• Strykowski R., Poonawalla M., Tyker A, Ventura I., Lee C., Jablonski R., Vij R., Chung J., Strek M., Adegunsoye A. (April 04, 2022) Mortality Risk From COVID-19 Among Unvaccinated Subjects with Autoimmune Phenotypes of Interstitial Lung Disease. Cureus 14(4): e23808. doi:10.7759/cureus.23808.
• Scarpato B.*, Strykowski R.*, Lawrence R., Khan S., Newman J., Khan S., Newman J., Spring M., Gupta V., Patel J., Cohen R., Sloan J., Nouraie S., Klings E. Risk factors for Venous Thromboembolism and clinical outcomes in adults with sickle cell disease. Thrombosis Update. In press, Journal Pre-proof. 2022 February. https://doi.org/10.1016/j.tru.2022.100101. *denotes co-authorship.
• Strykowski R., Adegunsoye A. Molecular Pathways in Idiopathic Pulmonary Fibrosis Pathogenesis: Transcending Barriers to Optimally Targeted Pharmacotherapies. EBioMedicine. 2021 May;67:103373
• Tyker, A., Ventura, I.B., Lee, C.T., Strykowski, R., Nicole Garcia et al. High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease. Sci Rep 11, 22821 (2021). https://doi.org/10.1038/s41598-021-02066-9.
• Gupta, V., Strykowski, R., Scarpato, B., Lawrence, R., Khan, S., Patel, J., Seyed-Mehdi, N., Cohen, R., Sloan, M., and Klings, E. (2020) The effect of anticoagulant choice on venous thromboembolism recurrence and bleeding in sickle cell disease. American Journal of Hematology (July, 2020) https://doi.org/10.1002/ajh.25923.